TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06582901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)
Description: Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced - Treatment as Usual
Description: The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT). Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
Study: NCT04799964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Diverter (Tonbridge)
Description: The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tubridge (MicroPort)
Description: Tubridge consists of a stent system and a microcatheter system. The stent system consists of a stent and a conveyor, the stent is self-expanding as well.
Study: NCT05964842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Participants in this arm will receive three SMS reminders. The first SMS will be sent on day one after enrollment into the study. The second SMS will be sent once participant results are ready. If two days after the second SMS the patient has not returned to complete TB diagnosis, a third SMS will be sent. Messages will be automatically sent in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call
Description: Participants in this arm will receive three phone call reminders. The first phone call will be made on day one after enrollment into the study. The second phone call will be made once participant results are ready. If two days after the second phone call the patient has not returned to complete TB diagnosis, a third phone call will be made. Phone calls will be made in either English or Luganda, the commonly spoken local language in the study area. The preferred language of the participant will be determined at enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile money incentive
Description: Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile money incentive
Description: Once participants in the study arms with mobile money complete TB diagnosis by submitting a sputum sample and collecting back results, a money incentive worth 20,000/= (Twenty thousand shillings only) will be given as a transport refund sent via mobile money.
Study: NCT04488679

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: direct pulp capping
Description: teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: direct pulp capping
Description: teeth with exposed pulp during caries removal will be capped either with PRF followed by mta or mta alone directly on exposed pulp, in both groups restoration will be placed over mta
Study: NCT06540261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7913
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7913
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofolinate
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study: NCT05796583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Pulsed Shortwave Treatment
Description: Application of 8 days of nonthermal, pulsed shortwave (radiofrequency) therapy with Endonovo Therapeutics SofPulse

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Application of 8 days of a nonfunctional sham device
Study: NCT05277766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC with Nal-IRI
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
Study: NCT06472427

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Normoxic recovery and placebo (NPL)
Description: Altitude: sea level Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normoxic recovery and ketones (NKE)
Description: Altitude: sea level Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypoxic recovery and placebo (HPL)
Description: Altitude: 3,000m (simulated) Dietary supplement: placebo. Water: 98.3% w/w Bitter flavour type: 0.7% w/w Monk fruit extract: 0.04% w/w Tasteva: 0.03% w/w Citric acid: 0.6% w/w Flavor blend: 0.02% w/w Bitter masking flavour: 0.2% w/w Passion fruit flavour: 0.005% w/w

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypoxic recovery and ketones (HKE)
Description: Altitude: 3,000m (simulated) Dietary supplement: Commercially available Ketone-IQ butanediol drink R-1,3-butanediol: 28.6% w/v in water
Study: NCT05444855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Leader Model
Description: Teens will have an opportunity to interact with established peer leaders that are a part of the AccessKCTeen program. These leaders will receive a baseline training of their role, sexual and mental health. They will also receive health education and engage with a peer liaison via text messages throughout the study.
Study: NCT05258721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClōSYS® Sensitive Fluoride Toothpaste
Description: ClōSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ClōSYS® Sensitive Rinse
Description: ClōSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.
Study: NCT05569044

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution
Description: Participants will be administered ORS during one of the study visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Participants will be administered water during one of the study visits
Study: NCT05058339

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT05328102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plamotamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plamotamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plamotamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Biological

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tafasitamab
Description: Biological

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Drug
Study: NCT06492122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [225Ac]Ac-FL-020
Description: \[225Ac\]Ac-FL-020 injected intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blood samples for PK
Description: Following the first injection of \[225Ac\]Ac-FL-020, blood samples after treatment will be collected for PK evaluation.
Study: NCT05516446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB for de Novo Lesions
Description: The surface of the SeQuent® Please NEO balloon is coated with Paclitaxel at a concentration of 3 μg Paclitaxel per mm² of balloon surface. The matrix composed of Paclitaxel and Iopromide (Paccocath technology) allows homogeneous release of the active ingredient through the vessel surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DES for de Novo Lesions
Description: The latest generation DES : everolimus-eluting platinum-chromium alloy coronary stent system (Promus Premier, Promus Elite)
Study: NCT04094558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible capsule
Description: Participants will swallow capsules and collect in stool concurrent with stool samples

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible capsule
Description: Participants will swallow capsules and collect in stool concurrent with stool samples

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ingestible capsule
Description: Participants will swallow capsules and collect in stool concurrent with stool samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated EGD
Description: Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated EGD
Description: Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated EGD
Description: Participants will undergo sedated esophagogastroduodenoscopy (EGD) for collection of small intestine aspirate and simultaneous saliva sample.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Hydrogen and methane breath test with lactulose substrate

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Hydrogen and methane breath test with lactulose substrate

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose Breath Test
Description: Hydrogen and methane breath test with lactulose substrate
Study: NCT06000228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recession coverage with CTG using minimally invasive access technique in shallow vestibule
Description: After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recession coverage with CTG using minimally invasive access technique in deep vestibule
Description: After enrolment, participants will be instructed about oral hygiene and undergo nonsurgical periodontal treatment in the form of scaling and root planing using ultrasonic and hand instruments as needed. After resolution of inflammation, a full thickness tunnel will be preapred using minimally invasive access technique under local anesthesia with the aid of specific tunnelling instruments and connective tissue graft will be procured from the palate or tuberosity area for root coverage procedure by single incision technique.
Study: NCT06474338

Intervention type: DIAGNOSTIC_TEST
Intervention: detection by artificial intelligence
Description: The bladder lesion(s) are detected by artificial intelligence algorithm.

Intervention type: DIAGNOSTIC_TEST
Intervention: detection by urologists
Description: The bladder lesion(s) are detected by urologists.
Study: NCT04298047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participatory art-based activity
Description: The intervention is a 3-month cycle of weekly guided tours carried out at the MMFA. Each visit will be performed with a group of 8 participants and a trained guide. They will meet at the museum once per week for a 45 min museum guided tour during a 3-month period. Each visit will be different and supervised by a museum guide. Regardless the topic of the visits, each visit will be standardized and separated in two consecutive phases: (1) Presentation of the objectives of the activity and (2) tour with a guide. Guided tours will target visual art (i.e., painting). They will be tailor-made and based on emotions and interactions in front of painting. The levels of information given to participants will regularly (i.e., each month) increase during the 3-month cycle of museum guided tours. The participants will be separated in 8 groups of 8 individuals per week. The same guide will manage each group of 8 participants during the 12 planned visits.
Study: NCT05459363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-THINC
Description: Improved Training Happens with Integrated Neuromuscular and Cognitive Challenge (I-THINC) is an injury prevention program. It will be used to integrate cognitive tasks with traditional sports injury prevention approaches that focus on balance, agility, and neuromuscular control.
Study: NCT06199843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550 mg BD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norfloxacin
Description: Norfloxacin 400 mg OD
Study: NCT06492122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [111In]In-FL-020
Description: A dose of \[111In\]In-FL-020 will be injected prior to the first dose of \[225Ac\]Ac-FL-020 for dosimetry evaluation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and urine samples collection
Description: For dosimetry evaluation and urine excretion assessment, blood and urine samples will be collected after the injection of \[111In\]In-FL-020

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPECT/CT images
Description: For dosimetry evaluation, SPECT/CTs will be performed following the injection of \[111In\]In-FL-020.
Study: NCT06599671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal niche resection
Description: In short: the bladder was carefully dissected away from the uterus towards the abdominal cavity to open the vesicovaginal space and reach the peritoneum. The fingers on the anterior wall isthmus could touch the obvious scar-like defect. The weak scar tissue then thoroughly was removed.
Study: NCT05724589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidermal Growth Factor
Description: Apply facial twice daily.
Study: NCT05900362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalCare Platform
Description: All participants will receive an VitalCare platform with tablet, Eko Duo with capability to record heart/lung sounds, blood pressure cuff, pulse oximetry and digital scale
Study: NCT05146180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parametric positron emission computed tomography
Description: Patients will undergo parametric positron emission computed tomography in 15 days after the labeled polynuclear scintigraphy
Study: NCT04824339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Group
Description: This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Intervention Group
Description: This study is a partial cross over study. The intervention is 8 weeks in duration. Participants will be randomized to immediate exercise or delayed exercise, and the delayed exercise group will cross over to the intervention after 8 weeks.
Study: NCT06464601

Intervention type: COMBINATION_PRODUCT
Intervention: fruquintinib combined with immune checkpoint inhibitors and chemotherapy
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.

Intervention type: COMBINATION_PRODUCT
Intervention: fruquintinib combined with immune checkpoint inhibitors and chemotherapy
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: XELOX or SOX.~Immune Checkpoint Inhibitors:~Selection based on clinical guidelines/indications and patient condition, including but not limited to PD-1 inhibitors, PD-L1 inhibitors.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.
Study: NCT05713656

Intervention type: OTHER
Intervention: Physiotherapy care
Description: Physiotherapy care including a bike fit, education and exercises provided by a physiotherapist with a BikePT bronze to gold certification.
Study: NCT04646473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetGoals app
Description: App offers goal setting and feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetGoals app
Description: App offers goal setting and feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetGoals app
Description: App offers goal setting and feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetGoals app
Description: App offers goal setting and feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Web health coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Web health coaching

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Financial incentives for meeting goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Financial incentives for meeting goals